GlassScriptPhysician profile
Maria C Aloba
NPI 1306923180
$77,424.29
in general payments reported to CMS, 2019-2025
42 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $2,169 · 2021: $16K · 2022: $7,629 · 2023: $11K · 2024: $211 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Honoraria: $6,525 · Travel and Lodging: $1,934 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Food and Beverage: $564 · Education: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,815.00 |
| Honoraria | $6,525.00 |
| Travel and Lodging | $1,933.84 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Food and Beverage | $563.50 |
| Education | $429.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $8,511.08 | 2019 | |
| Merck Sharp & Dohme LLC | $8,383.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $6,609.26 | 2019-2022 | |
| Novocure INC. | $5,584.40 | 2023 | Optune |
| Astrazeneca Pharmaceuticals LP | $4,700.94 | 2019-2024 | Enhertu |
| Rigel Pharmaceuticals, INC. | $4,386.03 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $3,831.87 | 2020-2022 | |
| Exelixis INC. | $3,275.68 | 2025 | Cabometyx |
| G1 Therapeutics, INC. | $3,000.00 | 2021 | |
| Cti Biopharma Corp. | $2,975.00 | 2022-2023 | Vonjo |
| Fresenius Kabi USA, LLC | $2,620.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $2,617.80 | 2023-2025 | Jemperli, Ojjaara |
| Epizyme, INC. | $2,500.00 | 2021 | |
| Janssen Biotech, INC. | $2,059.43 | 2021-2025 | Rybrevant |
| Lilly USA, LLC | $2,000.00 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Aloba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.